Prevalence and determinants of adherence to HAART amongst PLHIV in a tertiary health facility in south-south Nigeria

BMC Infectious Diseases

Angela Oyo-ita¹  Olusimbo K Ige²  Eme T Owoaje²  Afiong O Oku¹ 

[1] Department of Community Medicine, University of Calabar Teaching Hospital, Calabar, Cross river state, Nigeria;Department of Community Medicine, University College Hospital, Ibadan, Nigeria

关键词: Nigeria;    Cross river;    PLHIV, HAART;    Adherence;   

Others  :  1145916
DOI  :  10.1186/1471-2334-13-401

 received in 2013-03-01, accepted in 2013-08-21,  发布年份 2013

【 摘 要 】

Background

Adherence to Highly active antiretroviral therapy (HAART) is a major predictor of the success of HIV/AIDS treatment. Good adherence to HAART is necessary to achieve the best virologic response, lower the risk of drug resistance and reduce morbidity and mortality. This study therefore aimed to determine the prevalence and determinants of adherence to HAART amongst PLHIV accessing treatment in a tertiary location in Cross River State, Nigeria.

Methods

A cross-sectional study was conducted among patients on HAART attending the Presidential Emergency plan for AIDS relief (PEPFAR) clinic of the University of Calabar Teaching Hospital between October–December 2011. A total of 411 PLHIV visiting the study site during the study period were interviewed. PLHIV who met the inclusion criteria were consecutively recruited into the study till the desired sample size was attained. Information was obtained from participants using a semi-structured, pretested, interviewer administered questionnaire. Adherence was measured via patients self report and were termed adherent if they took at least 95% of prescribed medication in the previous week prior to the study. Data were summarized using proportions, and χ² test was used to explore associations between categorical variables. Predictors of adherence to HAART were determined by binary logistic regression. Level of significance was set at p < 0.05.

Results

The mean age of PLHIV who accessed treatment was 35.7 ± 9.32 years. Females constituted 68.6% of all participants. The self reported adherence rate based on a one week recall prior to the study was 59.9%. The major reasons cited by respondents for skipping doses were operating a busy schedule, simply forgot medications, felt depressed, and travelling out of town. On logistic regression analysis, perceived improved health status [OR 3.11; CI: 1.58-6.11], reduced pill load [OR 1.25; 95% CI: 0.46-2.72] and non-use of herbal remedies [OR 1.83; 95% CI: 1.22-2.72] were the major predictors for adherence to HAART. However, payment for ART services significantly decreased the likelihood of adherence to HAART. [OR 0.46; 95% CI: 0.25-0.87.].

Conclusions

The adherence rate reported in this study was quite low. Appropriate adherence enhancing intervention strategies targeted at reducing pill load and ensuring an uninterrupted access to free services regimen is strongly recommended.

【 授权许可】

   
2013 Oku et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]UNAIDS: 2008 Report on the global. HIV/AIDS epidemic 2008. Geneva Switzerland; 2008.
• [2]Federal Ministry of Health(FMOH): 2010 National HIV sero- prevalence Senntinnel Survey. Abuja: Federal Ministry of Health; 2010.
• [3]Rao D, Kekwaletswe TC, Hosek S, Martinez J, Rodriguez F: Stigma and social barriers to medication adherence with urban youth living with HIV. AIDS Care 2007, 19(1):28-33.
• [4]Lewis MP, Colbert A, Erlen J, Meyers M: A Qualitative study of persons who are 100% adherent to antiretroviral therapy. AIDS Care 2006, 18(2):140-148.
• [5]Moatti JP, Spire B: Economic and socio-behavioral issues related to highly active antiretroviral therapies for HIV infection: the contribution of social science research. Med Sci 2003, 19(8):878-884.
• [6]Tapper M, Flexner C, Eron JJ, Molina J: Simplifying antiretroviral therapy. AIDS Care 2004, 14(7):355-367.
• [7]National Agency for the control of AIDS (NACA): Antiretroviral therapy(ART) in Nigeria. Fact sheet 2011 2011.
• [8]McPherson-Baker S, Jones D, Duran R, Klimas N, Schneiderman N: Development and implementation of a medication adherence training instrument for persons living with HIV (The MATI). Behav Modif 2005, 29(2):286-317.
• [9]Amico KR, Toro-Alfonso J, Fisher JD: An empirical test of the Information, Motivation and Behavioural Skills model of antiretroviral therapy adherence. AIDS Care 2005, 17(6):661-673.
• [10]Remien RH, Bastos FI, Terto Jnr V, Raxach JC, Pinto RM, Parker RG, et al.: Adherence to antiretroviral therapy in a context of universal access, in Rio de Janeiro, Brazil. AIDS Care 2007, 19(6):740-748.
• [11]Weiser S, Wolfe W, Bangsberg D: Barriers to Antiretroviral Adherence to patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr 2003, 34(3):281-288.
• [12]Weiss L, French T, Finkelstein R, Waters M, Mukherjee RBA: HIV-related knowledge and adherence to HAART. AIDS Care 2003, 15(5):673-679.
• [13]Paterson G, Swindells S, Mohr J: Adherence to protease inhibitor therapy and outcome in patients with HIV infection. Ann Intern Med 2000, 133:21-30.
• [14]Nilsson-Schönnesson L, Diamond PM, Ross MW, Williams M, Bratt G: Baseline predictors of three types of antiretroviral therapy (ART) adherence A 2-year follow-up. AIDS Care 2006, 18(3):246-253.
• [15]Poppa A, Davidson D, Deutsch J, Dan G, Fisher M, Head S: British HIV Association (BHIVA)/British Association for sexual health and HIV (N‘BASHH) guidelines on provision of adherence support to individuals receiving antiretroviral therapy. HIV Med 2004, 5(S):46-60.
• [16]Reynolds NR, Testa M, Marc L, Chesney M, Neidig J, Smith S, et al.: Factors influencing medication adherence beliefs and self-efficacy in persons naïve to antiretroviral therapy: A multicentre, cross-sectional study. AIDS Behaviour 2004, 8(2):141-150.
• [17]Mohammed MD: R. S. Adherence to antiretroviral drugs in North-Central zone of Nigeria. East Cent Afr J Pharm Sci 2004, 7(3):52-55.
• [18]Iliyasu I, Kabir M, Abubakar I, Babashani M, Zubair Z: Compliance to antiretroviral therapy among AIDS patients in Amino Kano Teaching Hospital, Kano. Niger J Med 2005, 14(3):290-294.
• [19]Monjok E, Smesny A, Okokon IB, Mgbere O, Essien J: Adherence to antiretroviral therapy in Nigeria: An overview of research studies and implications for policy and practice. HIV/AIDS - Res Palliat Care 2010, 2:69-76.
• [20]Svarstad B, Chewning B, Sleath B, Claessonc C: The brief medication questionnaire: A tool for screening patient adherence and barriers to adherence. Patient Educ Couns 1998, 37:113-124.
• [21]Olowookere SA, Fatiregun AA, Akinyemi JO, Bamgboye AEGKO: Prevalence and determinants of nonadherence to highly active antiretroviral therapy among people living with HIV/AIDS in Ibadan, Nigeria. J Infect Dev Ctries 2008, 2(5):369-372.
• [22]Shaahu V, Lawoyin T, Sangowawa A: Adherence to Highly Active antiretroviral therapy(HAART) at a Federal Medical Center. Afr J Med Sci 2008, 37:29-36.
• [23]Agu KA, Okojie O, Oqua D, King RC, Omonaiye O, Onuoha C, et al.: Medication Adherence and Risk factors for Non-adherence among Patients taking Highly Active Antiretroviral Therapy. West Afr J Pharm 2011, 22(1):19-26.
• [24]Uzochukwu B, Onwujekwe O, Onoka A, Okoli C, Uguru N, Chukwuogo O: Determinants of non-adherence to subsidized anti-retroviral treatment in southeast Nigeria. Health Policy Plan 2009, 24:189-196.
• [25]Falang KD, Akubaka N, Jimam NS: Patient Factors impacting Antiretroviral drug adherence in a Nigerian tertiary Hospital. J Pharmacol Pharmacother 2012, 3(2):138-142.
• [26]Peltzer K: Preez NF-d, Ramlagan S, Anderson J: Antiretroviral treatment adherence among HIV patients in KwaZulu-Natal. South Afr BMC Public Health 2010, 10:1-10. BioMed Central Full Text
• [27]Amberbir A, Woldemichael K, Getachew S, Girma B, Deribe K: Predictors of adherence to antiretroviral therapy among HIV-infected persons: a prospective study in Southwest Ethiopia. BMC Publ Health 2008, 8(265):1-10.
• [28]Talaam NC, Gatongi P, Rotich S: Factors Affecting Antiretroviral Drug Adherence among HIV/AIDS Adult Patients attending HIV/AIDS clinic at Moi Teaching and Refferal Hospital, Eldoret, Kenya. East Afr J Public Health 2008, 5(2):74-78.
• [29]Wakibi SN, Ng’ang’a ZW, Mbugua GG: Factors associated with non-adherence to highly active antiretroviral therapy in Nairobi, Kenya. AIDS Res Ther 2011, 43:1-8.
• [30]Kacanek D, Jacobson D, Spiegelman D, Wancke C, Isac R, Wilson I: Incident depression symptoms are associated with poorer HAART adherence: A longitudinal analysis from the nutrition for Healthy living study (NFHL). J Acquir Immune Defic Syndr 2010, 53(2):266-272.
• [31]Kleeberger C, Phair J, Strathdee S, Detels R, Kingsley L, Jacobson L: Determinants of heterogenous adherence to HIV antiretroviral therapies in the Multicentre AIDS Cohort Study. J Acquir Immune Defic Syndr 2001, 26(1):82-92.
• [32]Gifford A, Bormann J, Shively M, Wright B, Richman D, Bozzette S: Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr 2000, 23:386-395.
• [33]Afolabi MO, Ijadunola KT, Fatusi AO, OA O: Determinants of adherence to antiretroviral drugs among people living with HIV/AIDS in the Ife-Ijesa of Osun State, Nigeria. Afr J Prim Health Care Fam Med 2009, 1(1):6.
• [34]Bello SI: HIV Patients adherence to ART in Sobi Specialist Hospital, Illorin. Nigeria Glob J Med Res 2011, 11(2):16-21.
• [35]Sow PG, Toure K, Coume M, Dia AT, Traore I: Predictors of ART adherence among HIV infected individuals in Dakar, Senegal. J Med Med Sci 2012, 3(4):212-216.
• [36]Cauldbeck MB, O'Connor C, O'Connor MB, Saunders JA, Rao B, Mallesh VG, et al.: Adherence to anti-retroviral therapy among HIV patients in Bangalore. India AIDS Res Ther 2009, 6(7):1-8.
• [37]Malcolm S, Ng J, Rosen R, Stone V: An examination of HIV/AIDS patients who have excellent adherence to HAART. AIDS Care 2003, 15(2):251-61.